The fresh wave of Covid-19 in the country has pushed up sales of medicines and resulted in exponential growth for the pharmaceutical sector. According to total sales audit data from world s largest pharmaceutical market research firm IMS Health, the Indian Pharma Market (IPM) grew 59 per cent yoy in April, 2021 vs 16 per cent yoy in March, 2021 due to the low base effect in April, 2020 and sharp surge in Covid-19-related sales. On the MAT (moving annual turnover) basis, IPM grew 9.6 per cent, primarily driven by pricing growth of 4.3 per cent and new product launch growth of 4.6 per cent. Volume growth was muted at 0.8 per cent.
Amid COVID Surge, Indian Pharma Sector Witnesses Exponential Growth In April 2021: Report
A Representative Image
The fresh wave of Covid-19 in the country has pushed up sales of medicines and resulted in exponential growth for the pharmaceutical sector.
According to total sales audit data from worldâs largest pharmaceutical market research firm IMS Health, the Indian Pharma Market (IPM) grew 59 per cent year on year (yoy) in April, 2021 vs 16 per cent yoy in March, 2021 due to the low base effect in April, 2020 and sharp surge in Covid-19-related sales.
On the MAT (moving annual turnover) basis, IPM grew 9.6 per cent, primarily driven by pricing growth of 4.3 per cent and new product launch growth of 4.6 per cent. Volume growth was muted at 0.8 per cent.
इन शेयरों की कीमतें 10 साल के औसत पीई से कम, क्या आप निवेश करेंगे? indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.
Investors poorer by Rs 8.69 lakh crore as Covid 2.0 spooks D-Street bulls
SECTIONS
Share
Synopsis
Further imposition of lockdowns and all-time high Covid-19 cases have dragged the market to a monthly low.
The S&P BSE Sensex index tumbled 1,897.88 points or 3.82% to hit 47,693.44 at the weakest level during the session.
Related
NSE
Explore Now
NEW DELHI: As India recorded its highest ever surge in new Covid-19 cases, investors dumped whatever they could get their hands on, pushing benchmark indices downhill on Monday. A weakening rupee also made Dalal Street equities unattractive.
Further imposition of lockdowns and all-time high Covid-19 cases have dragged the market to a monthly low. This is expected to impact economic growth in the first quarter of FY22 by a wider margin than anticipated earlier.
Pharma Shares Gain On Higher Demand For Medicines As Covid-19 Cases Rise Pharma Shares Gain On Higher Demand For Medicines As Covid-19 Cases Rise Rising Covid-19 cases in the country is leading to higher demand for medicines which is driving up the share prices of drugmakers, analysts said.
Updated: April 12, 2021 12:30 pm IST
Shares of pharma companies were outperforming in an otherwise weak market session as rising demand for medicines amid rising Coronavirus infections in country led to investors buying shares of pharma companies.
The gauge of pharma shares on the National Stock Exchange rose 1.4 per cent massively outperforming the Nifty 50 index which was down 3.58 per cent.